Literature DB >> 15472196

Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency.

R Bouillon1, E Koledova, O Bezlepkina, J Nijs, E Shavrikhova, E Nagaeva, O Chikulaeva, V Peterkova, I Dedov, A Bakulin, V Oganov, A F Attanasio.   

Abstract

The consequences of lifelong untreated childhood-onset GH deficiency (COGHD) on adult bone and especially fracture prevalence are largely unknown due to the lack of data on long-term outcome of untreated patients. Therefore, we studied adult Russian patients (n = 66; 28 females and 38 males) with idiopathic GH-untreated COGHD. Patients had isolated GH deficiency (IGHD; n = 18, age 23 +/- 10 yr) or multiple pituitary hormone deficiency (MPHD) with open (OMPHD; n = 27, age 23 +/- 5 yr) or closed growth plates (CMPHD; n = 21, age 55 +/- 12 yr). Bone mineral content (BMC) and bone mineral density (BMD) values were compared with 821 normal Russian controls. Fracture prevalence was ascertained from medical history and compared with similar data from 333 normal controls. Height sd score was -4.6 (range, -1.8 to -8.1). This represents 82% of the height of normal Russian adults. BMC of the lumbar spine, femoral neck, and total body of patients with IGHD was 54, 71, and 59%, respectively, of that of age- and sex-matched controls (all P < 0 0.001). A similarly decreased BMC (42-69% of expected values) was found for all bone regions of patients with both OMPHD and CMPHD. Mean areal BMD measurements (g/cm(2)) varied (Z scores between -1.8 and -3.0), but the calculated true bone density (g/cm(3)) was normal in patients with IGHD or CMPHD and only slightly decreased (Z score, -0.8) in patients with OMPHD. Lifetime low-energy fracture prevalence was normal in patients with IGHD but substantially exceeded the expected prevalence in OMPHD (odds ratio of fracture = 3.0; 0.6 fractures per patient; P < 0.0001) or CMPHD patients (odds ratio for fracture = 7.4; 2.2 fractures per patient; P < 0.0001). In conclusion, IGHD and MPHD of childhood onset very substantially impair adult height and BMC. Although areal BMD is frankly decreased, volumetric bone density is unaffected, but nevertheless, the fracture prevalence in patients with MPHD is markedly increased. These observations demonstrate that not only volumetric density but also bone mass and shape are major determinants of bone strength.

Entities:  

Mesh:

Year:  2004        PMID: 15472196     DOI: 10.1210/jc.2004-0054

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  The effect of growth hormone deficiency on size-corrected bone mineral measures in pre-pubertal children.

Authors:  M Gahlot; R Khadgawat; R Ramot; M Eunice; A C Ammini; N Gupta; M Kalaivani
Journal:  Osteoporos Int       Date:  2011-11-10       Impact factor: 4.507

2.  Skeletal health in adult growth hormone deficiency.

Authors:  Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-14       Impact factor: 3.633

Review 3.  Growth Hormone Deficiency: Health and Longevity.

Authors:  Manuel H Aguiar-Oliveira; Andrzej Bartke
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency.

Authors:  L Hyldstrup; G S Conway; K Racz; A Keller; P Chanson; M Zacharin; A L Lysgaard; A H Andreasen; A-M Kappelgaard
Journal:  Osteoporos Int       Date:  2011-11-29       Impact factor: 4.507

Review 5.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 6.  Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature.

Authors:  Xin He; Ariel L Barkan
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

Review 7.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 8.  IGF-1 and bone: New discoveries from mouse models.

Authors:  Shoshana Yakar; Hayden-William Courtland; David Clemmons
Journal:  J Bone Miner Res       Date:  2010-12       Impact factor: 6.741

9.  Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency.

Authors:  Erika Kristensen; Benedikt Hallgrímsson; Douglas W Morck; Steven K Boyd
Journal:  Int J Endocrinol       Date:  2012-03-13       Impact factor: 3.257

Review 10.  Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement.

Authors:  M Ahmid; C G Perry; S F Ahmed; M G Shaikh
Journal:  Endocr Connect       Date:  2016-04-29       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.